LA JOLLA, CA — August 14, 2025 — Leads & Copy — GRI Bio, Inc. (NASDAQ: GRI) will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, held virtually from August 19-21, 2025. The presentation is scheduled for Wednesday, August 20, 2025, at 2:20 PM ET, and will feature Marc Hertz, PhD, President, Chief Executive Officer and Director, as the presenter. GRI Bio is a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases.
Webull Financial is a platform empowering self-directed investors with tools and technology. GRI Bio focuses on changing the way inflammatory, fibrotic, and autoimmune diseases are treated, targeting Natural Killer T (“NKT”) cells to interrupt disease progression and restore the immune system. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity being developed as a novel oral therapeutic for idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for systemic lupus erythematosus and has a library of over 500 proprietary compounds.
Investor Contact:
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
Source: GRI Bio, Inc.
